FierceBiotechOriginal article
{"a":[{"_":"Teva autoimmune antibody notches ph. 2 win in celiac disease","$":{"href":"/biotech/teva-autoimmune-antibody-notches-ph-2-win-celiac-disease","hreflang":"en"}}]}
Phase 2positiveanti-interleukin-15 antibodyPositive
AI Analysis
Summary
Teva Pharmaceutical's anti-interleukin-15 antibody achieved positive Phase 2 results in celiac disease, advancing the company's first-in-class autoimmune program.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
anti-interleukin-15 antibody scored a midstage win in celiac disease
Importance:7/10
Sentiment:
0.75
autoimmuneceliac diseaseantibodyPhase 2first-in-class
Related Companies
Read the original article
Published by FierceBiotech on September 2, 2026 10:29 AM